Daniel Peter Silver MD
Associate professor, medical oncology and cancer biology
Join to View Full Profile
925 Chestnut StSte 420APhiladelphia, PA 19107
Phone+1 215-955-8874
Fax+1 215-503-2715
Dr. Silver is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 2000
University of California (San Francisco)Residency, Internal Medicine, 1994 - 1996- University of California San Francisco School of MedicineClass of 1994
Certifications & Licensure
PA State Medical License 2016 - 2026
NJ State Medical License 2017 - 2021
DE State Medical License 2017 - 2019
MA State Medical License 1996 - 2017
FL State Medical License 2012 - 2016
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2013-2015, 2017
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
Publications & Presentations
PubMed
- MECP2-Dependent Cancers Can Be Targeted by Epigenetic Drugs: A New Role for Epigenetic Cancer Therapy.Manish Neupane, Mukesh Kumar, Malela A Mwamufiya, Colleen M Donnelly, Alsu Ibragimova
Molecular Cancer Therapeutics. 2026-05-04 - 3 citationsPARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis.Ranju Kunwor, Daniel P Silver, Maysa Abu-Khalaf
Hematology/oncology and Stem Cell Therapy. 2023-04-04 - 3 citationsGenomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism.Maysa Abu-Khalaf, Chun Wang, Zhenchao Zhang, Rui Luo, Weelic Chong
Cancers. 2022-06-10
Press Mentions
HRD Score Did Not Predict Benefit of Platinum Therapy in TNBCSeptember 8th, 2020
Sidney Kimmel Cancer Center Scientists to Present on Uveal Melanoma, Biden Cancer Initiative and More at ASCO Annual MeetingJune 1st, 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
